864674-07-7

Basic information

• Product Name: 1-(2-benzoylpyridin-4-yl)-3-dimethylamino-2-propen-1-one
• Synonyms: 1-(2-benzoylpyridin-4-yl)-3-dimethylamino-2-propen-1-one
• CAS NO: 864674-07-7
• Molecular Weight: 280.326
• Mol File: 864674-07-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(2-benzoylpyridin-4-yl)-3-dimethylamino-2-propen-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-benzoylpyridin-4-yl)-3-dimethylamino-2-propen-1-one(864674-07-7)
• EPA Substance Registry System: 1-(2-benzoylpyridin-4-yl)-3-dimethylamino-2-propen-1-one(864674-07-7)

Safety Data

• Hazardous Substances Data: 864674-07-7(Hazardous Substances Data)

Upstream product

• 132883-96-6 1-(2-benzoylpyridin-4-yl)-ethanone 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Relevant articles and documents

2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5--a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula (I): The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula: (I) in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.